Biogen Inc. Files 8-K on Financials
Ticker: BIIB · Form: 8-K · Filed: Feb 12, 2025 · CIK: 875045
| Field | Detail |
|---|---|
| Company | Biogen Inc. (BIIB) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: BIIB
TL;DR
Biogen filed an 8-K on Feb 12, 2025, updating its financial condition and results.
AI Summary
Biogen Inc. filed an 8-K on February 12, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing details the company's status as a biological products manufacturer incorporated in Delaware.
Why It Matters
This filing provides an update on Biogen's financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- BIOGEN INC. (company) — Filer
- February 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 225 Binney Street, Cambridge, Massachusetts 02142 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Biogen Inc.'s Results of Operations and Financial Condition, and includes Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on February 12, 2025.
What is Biogen Inc.'s state of incorporation?
Biogen Inc. is incorporated in Delaware.
What is the principal executive office address for Biogen Inc.?
The principal executive office address is 225 Binney Street, Cambridge, Massachusetts 02142.
What is the SIC code for Biogen Inc.?
The Standard Industrial Classification (SIC) code for Biogen Inc. is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-12 07:06:19
Key Financial Figures
- $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select
Filing Documents
- biib-20250212.htm (8-K) — 24KB
- exhibit991-q42024pressrele.htm (EX-99.1) — 564KB
- newbiogenlogo.jpg (GRAPHIC) — 3KB
- 0000875045-25-000004.txt ( ) — 752KB
- biib-20250212.xsd (EX-101.SCH) — 2KB
- biib-20250212_lab.xml (EX-101.LAB) — 21KB
- biib-20250212_pre.xml (EX-101.PRE) — 12KB
- biib-20250212_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 12, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 99.1 Biogen's press release dated February 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOGEN INC. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: February 12, 2025